Similar therapeutic effects of 125I seed radiotherapy and γ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma

Li, Rui; Ge, Xin; Yang, Bentao; Zhang, Hong; Zhang, Jing-Xue; Ma, Jianmin

doi:10.18240/ijo.2021.04.11

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al [45] found that there was no significant difference in local control, control of metastasis to regional lymph nodes, or control of distant metastasis between the IR and ERBT groups. In the retrospective comparison case series, the clinical records of 27 patients with primary LGACC and 8 patients with recurrent LGACC were compared, and no statistically significant difference was found in the efficacies of IR and ERBT in terms of distant metastasis rates [16] . Previous studies have reported distant metastasis rates of 11%-56% and external radiation rates of 11%-67% for IR [7,17] .…”

Section: Discussionmentioning

confidence: 99%

Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis

Yan,

Wang,

et al. 2024

Int J Ophthalmol

View full text Add to dashboard Cite

AIM: To evaluate lacrimal gland adenoid cystic carcinoma (LGACC) of prognosis in patients who underwent different treatment regimens. METHODS: We searched PubMed, EMBASE, and the Cochrane Library for studies done on the treatment of LGACC, between January 1987 and April 2022. A Meta-analysis was conducted to pool the 5-year overall survival rate (OR), and the 5-year recurrence rate (RR) and 5-year metastasis rate (MR) were assessed. RESULTS: The 30 studies involved 585 patients were included in the Meta-analysis. The pooled 5-year OR with surgery alone was 50%, the 5-year RR was 63%, and the 5-year MR was 34%. The pooled 5-year OR with surgery and adjuvant radiotherapy combined was 67% (95%CI 61%,73%), the 5-year RR was 41%, and the 5-year MR was 35%. The pooled 5-year OR with surgery and adjuvant chemoradiotherapy combined was 72% (95%CI 59%, 84%), the 5-year RR was 48%, and the 5-year MR was 36%. The pooled 5-year OR with surgery, intra-arterial cytoreductive chemotherapy, and adjuvant chemoradiotherapy combined was 78% (95%CI 68%, 89%), the 5-year RR was 15%, and the 5-year MR was 27%. CONCLUSION: Comprehensive treatment is more effective than surgery alone. Surgery combined with intra-arterial chemotherapy and adjuvant chemoradiotherapy seems to add value to the therapeutic effect of comprehensive treatment of LGACC but further high-quality research is required to validate this.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis

Yan,

Wang,

et al. 2024

Int J Ophthalmol

View full text Add to dashboard Cite

show abstract

“… 4 , 16 Surgical resection combined with radiotherapy/chemotherapy, including 125 I implanted internal radiotherapy, local external radiotherapy, or transarterial interventional chemotherapy, is the most common approach used to treat patients with LGACC. 17 However, the clinical outcomes of these treatments are far from satisfactory. In recent years, targeted therapy has become a new strategy for cancer treatment, including targeted therapy for LGACC.…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland

Zhang¹,

Yan²,

Li³

et al. 2022

CMAR

Self Cite

View full text Add to dashboard Cite

Purpose Adenoid cystic carcinoma (ACC) of the lacrimal gland (LGACC) is an aggressive malignant lacrimal gland tumor with a generally poor prognosis. Survival rates for LGACC are 56% at 5 years and 49% at 10 years. Recent studies have indicated that anti-vascular endothelial growth factor (VEGF) therapy can inhibit angiogenesis in ACC cells. This study was designed to explore the efficacy of the antiangiogenic drug bevacizumab in a LGACC patient-derived xenograft (PDX) animal model. Methods The histological structure of PDX was determined by hematoxylin-eosin staining to confirm successful xenografting. Immunohistochemistry (IHC) was used to detect the expression of neovascularization-related genes in LGACC patients and in the PDX model, including VEGF, VEGFR1 , and FGFR . In order to compare the efficacy of antiangiogenic drug and traditional chemotherapy drug, PDX models were treated with bevacizumab and cisplatin respectively, and body weight was evaluated. Subsequently, the neovascularization-related proteins VEGF, VEGFR2, and CD34, tumor suppressor P53 and proliferation-related protein Ki67 were analyzed by IHC. Quantitative real-time PCR was employed to examine the mRNA expression of apoptosis-related genes BAD and Caspase 9, and of HIF1α. Results VEGF, VEGFR1 , and FGFR were highly expressed in patients with LGACC and PDX models. Both bevacizumab and cisplatin treatment inhibited PDX tumor growth. The body weight of PDX models treated with cisplatin significantly decreased from day 15, while those treated with bevacizumab did not markedly change. Bevacizumab reduced the expression of VEGF, CD34, and Ki67 in PDX tumors; whereas, bevacizumab upregulated P53 and downregulated HIF1α levels. Conclusion The present study indicates that antiangiogenic drugs may be a promising treatment strategy for LGACC.

show abstract

“…[8][9][10] The main mechanism of action for the use of 125 I is to place it at the tumor site and kill tumor cells directly using gamma rays (0.03548 MeV) released from its decay process, thereby partially or completely eliminating the lesions and avoiding the recurrence or distant metastasis. 11 In addition, 125 I can also serve as an imaging probe for nanocarriers (NCs), 12,13 tyrosine, and proteins 14,15 in theragnostics and drug tracing. 125 I labeling on the surface of NCs or proteins is well suited for the study of its physiological roles and metabolism due to its short half-life of 60.14 days.…”

Section: Introductionmentioning

confidence: 99%

Development of Small HN Linked Radionuclide Iodine-125 for Nanocarrier Image Tracing in Mouse Model

Ma,

Ji,

Shen

et al. 2024

IJN

View full text Add to dashboard Cite

Background Radionuclides have important roles in clinical tumor radiotherapy as they are used to kill tumor cells or as imaging agents for drug tracing. The application of radionuclides has been developing as an increasing number of nanomaterials are used to deliver radionuclides to tumor areas to kill tumor cells. However, promoting the efficient combination of radionuclides and nanocarriers (NCs), enhancing radionuclide loading efficiency, and avoiding environmental pollution caused by radionuclide overuse are important challenges that hinder their further development. Methods In the present study, a new small molecule compound (3-[[(2S)-2-hydroxy-3-(4-hydroxyphenyl)-1-carbonyl] amino]-alanine, abbreviation: HN, molecular formula: C 12 H 16 N 2 O 5 ) was synthesized as a linker between radionuclide iodine-125 ( 125 I) and NCs to enable a more efficient binding between NCs and radionuclides. Results In vitro evidence indicated that the linker was able to bind 125 I with higher efficiency (labeling efficiency >80%) than that of tyrosine, as well as various NCs, such as cellulose nanofibers, metal oxide NCs, and graphene oxide. Single-photon emission computed tomography/computed tomography imaging demonstrated the biological distribution of 125 I-labeled NCs in different organs/tissues after administration in mice. Conclusion These results showed an improvement in radionuclide labeling efficiency for nanocarriers and provided an approach for nanocarrier image tracing.

show abstract

Similar therapeutic effects of 125I seed radiotherapy and γ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma

Cited by 5 publications

References 27 publications

Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis

Treatment of lacrimal gland adenoid cystic carcinoma: a systematic review and Meta-analysis

Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland

Development of Small HN Linked Radionuclide Iodine-125 for Nanocarrier Image Tracing in Mouse Model

Contact Info

Product

Resources

About